Dn B Asset Management As Coherus Bio Sciences, Inc. Transaction History

Dn B Asset Management As

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 12, 2022	SELL	$15.81 - $18.99 $289,164 - $347,327	-18,290 Closed	0 $0
Q3 2021 Oct 15, 2021	SELL	$12.68 - $17.79 $55,322 - $77,617	-4,363 Reduced 19.26%	18,290 $293,000
Q2 2021 Jul 06, 2021	BUY	$12.95 - $15.41 $30,665 - $36,490	2,368 Added 11.67%	22,653 $313 Million
Q1 2021 Apr 15, 2021	SELL	$14.42 - $21.39 $10,699 - $15,871	-742 Reduced 3.53%	20,285 $296,000
Q4 2020 Jan 19, 2021	BUY	$16.56 - $18.94 $26,231 - $30,000	1,584 Added 8.15%	21,027 $365,000
Q3 2020 Oct 14, 2020	BUY	$17.41 - $19.89 $28,308 - $32,341	1,626 Added 9.13%	19,443 $356,000
Q2 2020 Jul 08, 2020	BUY	$14.43 - $19.16 $257,099 - $341,373	17,817 New	17,817 $318 Million

143

82.7M

79.1K

100K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $101M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

Stay updated on Dn B Asset Management As with notifications on news.